Endogenous mediators that inhibit the leukocyte-endothelium interaction

Trends Pharmacol Sci. 1997 Nov;18(11):418-25. doi: 10.1016/s0165-6147(97)01116-4.

Abstract

Leukocyte extravasation occurs in many pathophysiological conditions, including inflammation, neoplasia and asthma. In recent years many studies have elucidated the steps that promote the initial interaction between extravasating cells and endothelium of the post-capillary venule; the sequential role of several classes of adhesion molecules (cell-specific chemokines) and activators (multipotent cytokines) is well established. In this review, Mauro Perretti focuses on a less well investigated mechanism by which the host downregulates extravasation at the leukocyte-endothelium interface. The neutrophilic polymorphonuclear leukocyte is used as the prime example of a leukocyte that interacts with the endothelium, and particular emphasis is given to the possibility that novel anti-inflammatory therapies might be developed from a better understanding of the inhibitory mechanisms activated by endogenous mediators such as adenosine, lipocortin 1, NO, prostacyclin and cathepsin G.

Publication types

  • Review

MeSH terms

  • Animals
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiology*
  • Humans
  • Leukocytes / drug effects
  • Leukocytes / physiology*
  • Receptors, Cell Surface / drug effects
  • Receptors, Cell Surface / physiology*

Substances

  • Receptors, Cell Surface